Insights

BioNTech is no longer a buy, says analyst

A Bryan Garnier prognosticator increases her price target despite the recommendation chop.
The post BioNTech is no longer a buy, says analyst appeared first on The Motley Fool Australia. –

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

vaccine

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Despite some good news recently about the coronavirus vaccine it co-developed, BioNTech (NASDAQ: BNTX) has been hit with a recommendation downgrade.

In a research note published on Tuesday, Bryan Garnier analyst Olga Smolentseva changed her view on the stock to neutral from the previous buy recommendation. At the same time, though, she significantly raised her price target on the stock, from $135 per share to $206.

BioNTech shot to fame last year due to that vaccine, BNT162b2, which it co-developed with pharmaceutical giant Pfizer. Both became popular coronavirus stocks, particularly after the jab was authorized for emergency use in both the the U.S. and the European Union — two massive markets — in December.

This pushed BioNTech’s results high into the sky; last Friday, the company unveiled its first-quarter results, showing higher-than-expected revenue growth of nearly 7,300% and a flip deep into the black on the bottom line.

BNT162b2 should find its way into more American arms; on Monday, the FDA expanded its Emergency Use Authorization for the vaccine to include adolescents ages 12 to 15. The regulator quoted its acting commissioner, Janet Woodcock, as saying that this “allows for a younger population to be protected from COVID-19, bringing us closer to returning to a sense of normalcy and to ending the pandemic.”

But many investors might consider BioNTech’s explosive growth story to be over. In terms of both cases and fatalities, the pandemic is receding across the U.S., plus the Biden administration has indicated its support for patent waivers on coronavirus vaccines.

At any rate, Smolentseva’s new outlook on the stock isn’t doing it any favors. In late afternoon trading Tuesday, BioNTech was down by 2.2% while the S&P 500 index was falling 1.9%.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Where to invest $1,000 right now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now.

See The 5 Stocks

*Returns as of February 15th 2021

More reading

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

The post BioNTech is no longer a buy, says analyst appeared first on The Motley Fool Australia.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!